Stock Scorecard



Stock Summary for Liquidia Corp (LQDA) - $23.15 as of 10/28/2025 8:37:40 PM EST

Total Score

5 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LQDA

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LQDA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LQDA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LQDA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LQDA (40 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LQDA

Niagen Bioscience ( NAGE ) Reports Next Week: What to Expect 10/28/2025 2:00:00 PM
Arcutis Biotherapeutics, Inc. ( ARQT ) Q3 Earnings and Revenues Surpass Estimates 10/28/2025 1:35:00 PM
Wall Street Analysts Believe LIQUIDIA CORP ( LQDA ) Could Rally 50.94%: Here's is How to Trade 10/21/2025 1:55:00 PM
Smart Money Is Betting Big In LQDA Options - Liquidia ( NASDAQ:LQDA ) 10/8/2025 8:01:00 PM
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 10/7/2025 10:30:00 AM
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 - Liquidia ( NASDAQ:LQDA ) 10/7/2025 10:30:00 AM
Is IPF the Next Big Market Opportunity for United Therapeutics? 10/1/2025 2:40:00 PM
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting - Liquidia ( NASDAQ:LQDA ) 9/29/2025 12:30:00 PM
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association ( PHPN ) Symposium - Liquidia ( NASDAQ:LQDA ) 9/11/2025 12:30:00 PM
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association ( PHPN ) Symposium 9/11/2025 12:30:00 PM

Financial Details for LQDA

Company Overview

Ticker LQDA
Company Name Liquidia Corp
Country USA
Description Liquidia Technologies Inc. is a prominent biopharmaceutical company based in Morrisville, North Carolina, dedicated to advancing innovative therapies that address critical unmet medical needs. Leveraging its proprietary PRINT technology, the company excels in the precision manufacturing of drug particles, which enhances targeted delivery and therapeutic effectiveness. Liquidia's robust pipeline emphasizes the treatment of pulmonary hypertension and other serious health conditions, highlighting its strategic importance in the biopharmaceutical sector. With a steadfast commitment to improving patient outcomes and a focus on technological innovation, Liquidia is well-positioned for sustained growth in the evolving healthcare landscape.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 11/11/2025

Stock Price History

Last Day Price 23.15
Price 4 Years Ago 4.87
Last Day Price Updated 10/28/2025 8:37:40 PM EST
Last Day Volume 2,486,645
Average Daily Volume 2,609,574
52-Week High 29.94
52-Week Low 9.71
Last Price to 52 Week Low 138.41%

Valuation Measures

Trailing PE N/A
Industry PE 23.04
Sector PE 40.93
5-Year Average PE -11.43
Free Cash Flow Ratio 11.52
Industry Free Cash Flow Ratio 14.83
Sector Free Cash Flow Ratio 29.03
Current Ratio Most Recent Quarter 2.49
Total Cash Per Share 2.01
Book Value Per Share Most Recent Quarter 0.18
Price to Book Ratio 124.14
Industry Price to Book Ratio 29.98
Sector Price to Book Ratio 32.16
Price to Sales Ratio Twelve Trailing Months 99.72
Industry Price to Sales Ratio Twelve Trailing Months 33.56
Sector Price to Sales Ratio Twelve Trailing Months 16.96
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 86,091,000
Market Capitalization 1,993,006,650
Institutional Ownership 70.55%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -66.10%
Reported EPS 12 Trailing Months -1.82
Reported EPS Past Year -0.94
Reported EPS Prior Year -1.75
Net Income Twelve Trailing Months -141,470,000
Net Income Past Year -130,394,000
Net Income Prior Year -78,502,000
Quarterly Revenue Growth YOY 141.50%
5-Year Revenue Growth 11.64%
Operating Margin Twelve Trailing Months -424.40%

Balance Sheet

Total Cash Most Recent Quarter 173,422,000
Total Cash Past Year 176,479,000
Total Cash Prior Year 83,679,000
Net Cash Position Most Recent Quarter 23,952,000
Net Cash Position Past Year 79,108,000
Long Term Debt Past Year 97,371,000
Long Term Debt Prior Year 43,418,000
Total Debt Most Recent Quarter 149,470,000
Equity to Debt Ratio Past Year 0.44
Equity to Debt Ratio Most Recent Quarter 0.09
Total Stockholder Equity Past Year 77,275,000
Total Stockholder Equity Prior Year 47,293,000
Total Stockholder Equity Most Recent Quarter 15,189,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -123,977,000
Free Cash Flow Per Share Twelve Trailing Months -1.44
Free Cash Flow Past Year -98,371,000
Free Cash Flow Prior Year -42,854,000

Options

Put/Call Ratio 0.64
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.37
MACD Signal -0.35
20-Day Bollinger Lower Band 10.79
20-Day Bollinger Middle Band 20.95
20-Day Bollinger Upper Band 31.11
Beta 0.16
RSI 44.83
50-Day SMA 16.66
150-Day SMA 11.94
200-Day SMA 10.34

System

Modified 10/28/2025 4:00:38 AM EST